Current therapeutic approach in patients with Alzheimer disease;Attuale approccio terapeutico ai pazienti con malattia di Alzheimer

Recenti Progressi in Medicina

Volumn 98, Issue 5, 2007, Pages 293-301

  Ferlisi, Anna ^a   Dominguez, Ligia J ^a   Vernuccio, Laura ^a   Sutera, Loredana ^a   Bue, Anna Lo ^a   Di Prima, Anna ^a   Picciolo, Valentina ^a   Giambartino, Tanina ^a   Barbagallo, Mario ^a,b  

^a UNIVERSITY OF PALERMO   (Italy)

^b NONE   (Italy)

Author keywords

Alzheimer disease; Behavioral disturbance; Cholinesterase inhibitors; Cognitive impairment; Cognitive rehabilitation; Memantine

Indexed keywords

CHOLINESTERASE INHIBITOR; MEMANTINE;

ALZHEIMER DISEASE; BEHAVIOR DISORDER; CLINICAL FEATURE; COGNITION; COGNITIVE DEFECT; DRUG RESEARCH; HUMAN; REVIEW; TREATMENT OUTCOME;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; HUMANS;

EID: 34249294342     PISSN: 00341193     EISSN: 00341193     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Selkoe DJ. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nature Cell Biology 2004; 6: 1054-61.
2. Cummings JL. Alzheimer's disease. N Engl J Med 2004; 351: 56-67.
3. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease. A meta-analysis. JAMA 2003; 289: 210-6.
4. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002; 72: 708-12.
5. Feldman H, Gauthier S, Hecker J, Vellas B. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc 2003; 51: 737-44.
6. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomized double-blind trial. Lancet 2004; 363: 2105-15.
7. Wilkinson D, Doody R, Helme R, et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003; 61: 479-86.
8. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318: 633-8.
9. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ 2000; 321: 1445-9.
10. Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359: 1283-90.
11. Mendez MF, Shapira JS, McMurtray A, Licht E. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry 2007; 15: 84-7.
12. Knopman DS. Current treatment of mild cognitive impairment and Alzheimer's disease. Curr Neurol Neurosci Rep 2006; 6: 365-71.
13. Aorsland D, Hutchinson R, et al. Cognitive psychiatryc and major response to galantamine in Parkinson's disease with dementia. Eur Neuropsychofarm 2002, 12 : 5378-9.
14. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001; 57: 613-20.
15. Hauber AB, Gnanasakthy A, Mauskopf JA. Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine. Clin Ther 2000; 22: 439-51.
16. Orgogozo JM, Rigaud AS, Stoffler A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002; 33: 1834-9.
17. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348: 1333-41.
18. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291: 317-24.
19. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997; 336: 1216-22.
20. Shumaker SA, Legault C, Thal L, Wallace RB. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289: 2651-62.
21. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003; 289: 2819-26.
22. Birks J, Grimley EV, Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2002; 4: CD003120.
23. Naslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000; 283: 1571-7.
24. Siemers E, Skinner M, Dean RA, et al. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol 2005; 28: 126-32.
25. Aisen PS, Saumier D, Briand R, et al. A phase II study targeting amyloid-with 3APS in mild-to-moderate Alzheimer disease. Neurology 2006; 67: 1757-63.
26. McLaurin J, Cecal R, Kierstead ME, et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nature Med 2002; 8: 1263-9.
27. Orgogozo JM, Gilman S, Dartigues JF, Laurent B. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003; 61: 46-54.
28. Okura Y, Miyakoshi Y, Kohyama K, Park I, Staufenbiel M, Matsumoto Y. Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: long-term effects and safety. PNAS 2006; 103: 9619-24.
29. O'Donnell BF, Drachman DA, Barnes HJ, et al. Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol 1992; 5: 45-52.
30. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003; 289: 210-16.
31. McKeith I, Del Ser T, Spano P, Emre M. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031.
32. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999; 60: 107-15.
33. Ministero della Salute, Agenzia Italiana del Farmaco. Importanti informazioni di sicurezza su Risperdal e Belivon (risperidone) e rischio di eventi cerebrovascolari nel trattamento delle psicosi e dei disturbi comportamentali in pazienti anziani affetti da demenza. Bollettino d'informazione sui farmaci 2004; XI: 14.
34. Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002; 159: 460-5.
35. Gottfries CG, Karlsson I, Nyth AL. Treatment of depression in elderly patients with and without dementia disorders. Int Clin Psychopharmacol 1992; 6 Suppl 5: 55-64.
36. Lyketsos CG, Sheppard JM, Steele CD, et al. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Am J Psychiatry 2000; 157: 1686-9.
37. Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998; 155: 54-61.
38. Ballard CG, O'Brien JT, Reichelt K, Perry EK. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with Melissa. J Clin Psychiatry 2002; 63: 553-8.
39. Spector A, Orrell M, Davies S, et al. Reality orientation for dementia (Cochrane Review). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software.
40. Dubinsky RM, Stein AC, Lyons K. Practice parameter: risk of driving and Alzheimer's disease (an evidence-based review): Report of the quality standards. Subcommittee of the American Academy of Neurology. Neurology 2000; 54:2205-11.
41. Guo Z, Wills P, Viitanen M, et al. Cognitive impairment, drug use, and the risk of hip fracture in persons over 75 years old: a community-based prospective study. Am J Epidemiol 1998; 148: 887-92.
42. Pineo A, Dominguez LJ, Ferlisi A, et al. Violenza contro le persone anziane. Giornale di Gerontologia 2005; 53: 112-9.